Autolus Therapeutics plc (AUTL) AI Stock Analysis

Autolus Therapeutics plc is a London-headquartered clinical-stage biopharmaceutical company dedicated to advancing innovative T cell therapies for the treatment of cancer. The company develops programmed T cells targeting diverse oncological indications. Its clinical pipeline includes obecabtagene autoleucel (AUTO1), a CD19-targeting T cell therapy in Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL), as well as AUTO1/22 in Phase 1 trials for pediatric patients with relapsed or refractory ALL. Other pipeline assets include AUTO4 for peripheral T-cell lymphoma, AUTO8 in Phase I trials for multiple myeloma, and preclinical programs AUTO6NG targeting GD2 for neuroblastoma and AUTO5 for hematological indications.

Autolus has seen rapid top-line expansion, delivering a 5-year revenue compound annual growth rate of 113.2% from FY2020 to FY2025. Annual revenue grew 646.7% to $75.6M in FY2025, up from $10.1M in FY2024 and $1.7M in FY2023. Over the trailing twelve months, revenue reached $117.4M, aided by a 118.4% year-over-year revenue increase in the quarter ended June 30, 2026. However, heavy research and development investments, totaling $128.6M in FY2025, have led to persistent losses. Net loss expanded to -$288.2M in FY2025 with an operating margin of -372.4%. For the trailing twelve months, operating margin was -96.0%, profit margin was -238.6%, and diluted earnings per share stood at -$1.06.

As of June 30, 2026, Autolus held $201.6M in cash and short-term investments against $83.5M in total debt, resulting in net cash of $118.1M. The company had a current ratio of 4.89 and a debt-to-equity ratio of 1.12 on shareholders' equity of $74.8M. Operating cash flow in FY2025 was -$283.6M, and capital expenditures were $27.1M, yielding free cash flow of -$310.7M. The company pays no dividends and does not repurchase shares, with the common share count expanding 265.1% over five years to fund development.

Autolus trades at an enterprise value of $400.9M and a market capitalization of $425.9M. Its price-to-sales multiple is 3.6x, compared to a median of 4.1x for its US-listed Healthcare peers. The company has a price-to-book ratio of 6.9x and an enterprise value to revenue multiple of 3.4x. Shares have underperformed broader markets, falling 4.8% over the past year and 73.9% over five years, compared to gains of 16.8% and 83.0% for the S&P 500 (SPY) across the respective periods.

Wall Street sentiment is positive, with 8 Strong Buy ratings and 1 Buy rating among surveyed analysts. The mean price target is $8.72, representing a 445.3% premium over the October 16, 2026 close of $1.60. For the fiscal year ending December 31, 2026, analysts estimate revenue of $149.8M and an EPS of -$0.80. For FY2027, 8 analysts project revenue to expand 28.5% to $192.4M and EPS to reach -$0.64. The company beat EPS estimates in 1 of the last 4 quarters, and the next earnings release is scheduled for November 11, 2026.

This page is an AI-written research summary of Autolus Therapeutics plc (AUTL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AUTL income statement, AUTL balance sheet, AUTL key metrics, AUTL analyst forecast, AUTL chart. See the AUTL stock overview for the latest quote and news.